Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Percheron Therapeutics ( (AU:PER) ) has shared an update.
Percheron Therapeutics Limited has announced a change in the interest of its director, James Garner, with the acquisition of 5,000,000 unquoted options. These options were issued under the company’s Bonus Offer, as detailed in their prospectus filed with ASIC and ASX in early May 2025. This move reflects strategic financial adjustments and may influence the company’s market positioning and stakeholder interests.
The most recent analyst rating on (AU:PER) stock is a Buy with a A$0.24 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Average Trading Volume: 4,227,335
Technical Sentiment Signal: Sell
Current Market Cap: A$10.87M
For a thorough assessment of PER stock, go to TipRanks’ Stock Analysis page.